Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07565220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Aug 1, 2026 to Jul 27, 2026v3
  2. Recruitment opened Start date: Jun 1, 2026 to Aug 1, 2026 · Study description shortened, about 13 words · Site details revisedv2 Show 3 more changesShow less
    • Start date: Jun 1, 2026 to Aug 1, 2026
    • Study description shortened, about 13 words
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sawa Ito, MD
2 trials monitored
See 1 trial at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Acute Myeloid Leukemia (AML)
1,203 trials monitored
See 65 trials at risk
Acute Lymphoblastic Leukemia (ALL)
885 trials monitored
See 51 trials at risk
and 1 more disease
This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cyclophosphamide (PTCy) in HLA-matched related or unrelated donor allogeneic stem cell transplantation (alloSCT).
Trial Details
NCT Number NCT07565220
Lead Sponsor Sawa Ito, MD
Conditions Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS), Myeloproliferative Neoplasm (MPN)
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov